Skip to main content
. 2020 Jan 16;10:467. doi: 10.1038/s41598-019-57134-y

Figure 2.

Figure 2

AVP V1a and V2 receptor antagonist reverts the EAE-induced blood-brain barrier hyper-permeability to Evans blue. Graphs show the concentration (µg/g of tissue) of Evans blue dye in the brain (a) and spinal cord (b) of Intact Control (IC). Experimental Autoimmune Encephalomyelitis (EAE) and EAE plus conivaptan at 3 mg/kg (CO) (n = 6 per group). (a) Conivaptan treatment significantly reduced Evans blue dye concentration in the brain as compared with the EAE group. (b) Graph shows a trend toward a decrease in Evans blue extravasation in animals treated with conivaptan, but no significant differences were found as compared with the EAE group. (c) Representative images of Evans blue extravasation in the brain and spinal cord of intact control (IC), Experimental Autoimmune Encephalomyelitis (EAE) and EAE plus conivaptan at 3 mg/kg (CO) groups. Mean ± SD, Kruskal-Wallis test and Dunn´s post hoc test, **p < 0.01.